دورية أكاديمية
أعرض في EDS

miR-9-5p Exerts a Dual Role in Cervical Cancer and Targets Transcription Factor TWIST1.

التفاصيل البيبلوغرافية
العنوان: miR-9-5p Exerts a Dual Role in Cervical Cancer and Targets Transcription Factor TWIST1.
المؤلفون: Babion I; Cancer Center Amsterdam, Pathology, Amsterdam UMC, Vrije Universiteit Amsterdam, 1081 HV Amsterdam, The Netherlands., Jaspers A; Cancer Center Amsterdam, Pathology, Amsterdam UMC, Vrije Universiteit Amsterdam, 1081 HV Amsterdam, The Netherlands., van Splunter AP; Cancer Center Amsterdam, Pathology, Amsterdam UMC, Vrije Universiteit Amsterdam, 1081 HV Amsterdam, The Netherlands., van der Hoorn IAE; Cancer Center Amsterdam, Pathology, Amsterdam UMC, Vrije Universiteit Amsterdam, 1081 HV Amsterdam, The Netherlands., Wilting SM; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands., Steenbergen RDM; Cancer Center Amsterdam, Pathology, Amsterdam UMC, Vrije Universiteit Amsterdam, 1081 HV Amsterdam, The Netherlands.
المصدر: Cells [Cells] 2019 Dec 26; Vol. 9 (1). Date of Electronic Publication: 2019 Dec 26.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101600052 Publication Model: Electronic Cited Medium: Internet ISSN: 2073-4409 (Electronic) Linking ISSN: 20734409 NLM ISO Abbreviation: Cells Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI
مواضيع طبية MeSH: Gene Expression Regulation, Neoplastic* , RNA Interference*, MicroRNAs/*genetics , Nuclear Proteins/*genetics , Twist-Related Protein 1/*genetics , Uterine Cervical Neoplasms/*genetics, 3' Untranslated Regions ; Cell Line, Tumor ; Cell Proliferation ; DNA Methylation ; Female ; Human papillomavirus 16/genetics ; Human papillomavirus 18/genetics ; Humans ; Nuclear Proteins/metabolism ; Twist-Related Protein 1/metabolism ; Uterine Cervical Neoplasms/metabolism ; Uterine Cervical Neoplasms/pathology
مستخلص: Squamous cell carcinoma (SCC) and adenocarcinoma (AC) represent the major cervical cancer histotypes. Both histotypes are caused by infection with high-risk HPV (hrHPV) and are associated with deregulated microRNA expression. Histotype-dependent expression has been observed for miR-9-5p, showing increased expression in SCC and low expression in AC. Here, we studied the regulation and functionality of miR-9-5p in cervical SCCs and ACs using cervical tissue samples and hrHPV-containing cell lines. Expression and methylation analysis of cervical tissues revealed that low levels of miR-9-5p in ACs are linked to methylation of its precursor genes, particularly miR-9- 1. Stratification of tissue samples and hrHPV-containing cell lines suggested that miR-9-5p depends on both histotype and hrHPV type, with higher expression in SCCs and HPV16-positive cells. MiR-9-5p promoted cell viability and anchorage independence in cervical cancer cell lines SiHa (SCC, HPV16) and CaSki (metastasized SCC, HPV16), while it played a tumor suppressive role in HeLa (AC, HPV18). TWIST1, a transcription factor involved in epithelial-to-mesenchymal transition (EMT), was established as a novel miR-9-5p target. Our results show that miR-9-5p plays a dual role in cervical cancer in a histotype- and hrHPV type-dependent manner. MiR-9-5p mediated silencing of TWIST1 suggests two distinct mechanisms towards EMT in cervical cancer.
References: Clin Epigenetics. 2018 Jun 7;10:76. (PMID: 29930741)
Curr Chem Genom Transl Med. 2017 Jul 31;11:31-40. (PMID: 28868238)
Oncogene. 1996 Sep 19;13(6):1249-57. (PMID: 8808699)
J Natl Cancer Inst. 2001 Jun 6;93(11):865-72. (PMID: 11390536)
Nat Cell Biol. 2010 Mar;12(3):247-56. (PMID: 20173740)
Cell Physiol Biochem. 2019;52(5):1236-1250. (PMID: 31001962)
Methods. 2001 Dec;25(4):402-8. (PMID: 11846609)
Oncol Rep. 2015 Feb;33(2):639-50. (PMID: 25420506)
Int J Cancer. 2011 Apr 1;128(7):1596-605. (PMID: 20499310)
Int J Biochem Cell Biol. 2019 Jul;112:61-71. (PMID: 30959202)
Int J Cancer. 2015 Mar 1;136(5):E359-86. (PMID: 25220842)
Curr Genomics. 2014 Aug;15(4):310-23. (PMID: 25132800)
J Clin Microbiol. 2014 Nov;52(11):3996-4002. (PMID: 25210073)
J Clin Invest. 2009 Jun;119(6):1420-8. (PMID: 19487818)
Semin Cancer Biol. 2012 Oct;22(5-6):396-403. (PMID: 22554795)
Transl Oncol. 2019 Mar;12(3):576-584. (PMID: 30660934)
J Clin Microbiol. 1997 Mar;35(3):791-5. (PMID: 9041439)
Cancer Res. 2005 Feb 15;65(4):1271-6. (PMID: 15735012)
Oncotarget. 2014 Nov 30;5(22):11669-80. (PMID: 25375090)
PLoS One. 2018 Feb 22;13(2):e0193340. (PMID: 29470526)
Oncol Rep. 2012 Apr;27(4):1027-34. (PMID: 22245869)
Cancer Res. 2003 Nov 1;63(21):7215-20. (PMID: 14612516)
J Natl Cancer Inst. 2004 Feb 18;96(4):294-305. (PMID: 14970278)
Nat Rev Cancer. 2014 Jun;14(6):395-405. (PMID: 24854082)
Nature. 2017 Mar 16;543(7645):378-384. (PMID: 28112728)
J Virol. 2015 Oct;89(20):10680-7. (PMID: 26269181)
BMC Cancer. 2012 Nov 23;12:551. (PMID: 23176198)
PLoS One. 2016 Jul 22;11(7):e0159601. (PMID: 27447934)
Tumour Biol. 2016 Jan;37(1):185-97. (PMID: 26602382)
Biochem Biophys Res Commun. 2008 Mar 7;367(2):235-41. (PMID: 18062917)
BMC Cancer. 2011 Feb 01;11:49. (PMID: 21284870)
J Pathol. 2006 Jun;209(2):220-30. (PMID: 16538612)
Eur J Cancer. 2014 Jan;50(1):85-98. (PMID: 24054023)
Br J Cancer. 2007 Nov 19;97(10):1457-64. (PMID: 17971771)
Clin Transl Oncol. 2014 May;16(5):469-75. (PMID: 24019037)
Clin Cancer Res. 2013 Apr 15;19(8):2154-62. (PMID: 23459718)
EMBO J. 2012 Jan 4;31(1):110-23. (PMID: 21983900)
Exp Ther Med. 2017 Apr;13(4):1203-1208. (PMID: 28413458)
Sci Rep. 2019 Feb 19;9(1):2306. (PMID: 30783190)
Int J Cancer. 2002 Jan 1;97(1):72-81. (PMID: 11774246)
J Pathol. 2011 Aug;224(4):484-95. (PMID: 21503900)
Biomed Pharmacother. 2018 Jun;102:626-632. (PMID: 29602130)
mBio. 2017 Jan 3;8(1):. (PMID: 28049151)
Clin Cancer Res. 2012 Dec 1;18(23):6416-25. (PMID: 23045246)
Cells. 2018 Jul 16;7(7):. (PMID: 30012957)
Cancer Lett. 2015 Jan 28;356(2 Pt B):321-31. (PMID: 25281477)
Carcinogenesis. 2014 Nov;35(11):2611-8. (PMID: 25233927)
Mol Carcinog. 2016 May;55(5):732-42. (PMID: 25809226)
J Cell Sci. 2011 Oct 1;124(Pt 19):3189-97. (PMID: 21940791)
J Pathol. 1999 Sep;189(1):12-9. (PMID: 10451482)
Cell Mol Biol Lett. 2017 Nov 02;22:22. (PMID: 29118814)
Oncogene. 2013 Jan 3;32(1):106-16. (PMID: 22330141)
Oncotarget. 2014 Nov 30;5(22):11620-30. (PMID: 25344913)
Anat Rec (Hoboken). 2017 Dec;300(12):2184-2191. (PMID: 28921916)
Cell. 2006 Sep 22;126(6):1203-17. (PMID: 16990141)
Arch Gynecol Obstet. 2015 Oct;292(4):905-13. (PMID: 25851497)
Oncotarget. 2018 Apr 17;9(29):20838-20854. (PMID: 29755694)
Elife. 2015 Aug 12;4:. (PMID: 26267216)
معلومات مُعتمدة: KWF2012-5708 KWF Kankerbestrijding; ERC advanced 2012-AdG, proposal 322986; Mass-care International ERC_ European Research Council
فهرسة مساهمة: Keywords: HPV; TWIST1; cervical cancer; methylation; miR-9-5p
المشرفين على المادة: 0 (3' Untranslated Regions)
0 (MIRN92 microRNA, human)
0 (MicroRNAs)
0 (Nuclear Proteins)
0 (TWIST1 protein, human)
0 (Twist-Related Protein 1)
تواريخ الأحداث: Date Created: 20200101 Date Completed: 20200903 Latest Revision: 20231103
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC7017350
DOI: 10.3390/cells9010065
PMID: 31888045
قاعدة البيانات: MEDLINE
الوصف
تدمد:2073-4409
DOI:10.3390/cells9010065